Literature DB >> 34357138

The Skeletal Muscle Emerges as a New Disease Target in Amyotrophic Lateral Sclerosis.

Oihane Pikatza-Menoio1,2, Amaia Elicegui1,2, Xabier Bengoetxea1, Neia Naldaiz-Gastesi1,2, Adolfo López de Munain1,2,3,4, Gorka Gerenu1,2,5, Francisco Javier Gil-Bea1,2, Sonia Alonso-Martín1,2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that leads to progressive degeneration of motor neurons (MNs) and severe muscle atrophy without effective treatment. Most research on ALS has been focused on the study of MNs and supporting cells of the central nervous system. Strikingly, the recent observations of pathological changes in muscle occurring before disease onset and independent from MN degeneration have bolstered the interest for the study of muscle tissue as a potential target for delivery of therapies for ALS. Skeletal muscle has just been described as a tissue with an important secretory function that is toxic to MNs in the context of ALS. Moreover, a fine-tuning balance between biosynthetic and atrophic pathways is necessary to induce myogenesis for muscle tissue repair. Compromising this response due to primary metabolic abnormalities in the muscle could trigger defective muscle regeneration and neuromuscular junction restoration, with deleterious consequences for MNs and thereby hastening the development of ALS. However, it remains puzzling how backward signaling from the muscle could impinge on MN death. This review provides a comprehensive analysis on the current state-of-the-art of the role of the skeletal muscle in ALS, highlighting its contribution to the neurodegeneration in ALS through backward-signaling processes as a newly uncovered mechanism for a peripheral etiopathogenesis of the disease.

Entities:  

Keywords:  ALS; distal axonopathy; metabolism; neuromuscular disorder; neuromuscular junction; skeletal muscle; vesicles

Year:  2021        PMID: 34357138     DOI: 10.3390/jpm11070671

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  6 in total

Review 1.  Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.

Authors:  Elisabetta Meacci; Federica Pierucci; Mercedes Garcia-Gil
Journal:  Biomedicines       Date:  2022-05-04

2.  Impaired signaling for neuromuscular synaptic maintenance is a feature of Motor Neuron Disease.

Authors:  Qiao Ding; Kaamini Kesavan; Robert D Henderson; Pamela A McCombe; Rosalind L Jeffree; William D Phillips; Ernst J Wolvetang; Shyuan T Ngo; Peter G Noakes; Kah Meng Lee; Elyse Wimberger; Thomas Robertson; Melinder Gill; Dominique Power; Jeryn Chang; Atefeh T Fard; Jessica C Mar; Susan Heggie; Michael J Colditz; Massimo A Hilliard; Dominic C H Ng; Frederik J Steyn
Journal:  Acta Neuropathol Commun       Date:  2022-04-25       Impact factor: 7.578

3.  Bisperoxovanadium promotes motor neuron survival and neuromuscular innervation in amyotrophic lateral sclerosis.

Authors:  Junmei Wang; Lydia Tierney; Ranjeet Mann; Thomas Lonsway; Chandler L Walker
Journal:  Mol Brain       Date:  2021-10-11       Impact factor: 4.041

4.  Contingent intramuscular boosting of P2XR7 axis improves motor function in transgenic ALS mice.

Authors:  Paola Fabbrizio; Jessica D'Agostino; Cassandra Margotta; Giulia Mella; Nicolò Panini; Laura Pasetto; Eliana Sammali; Flavia Raggi; Gianni Sorarù; Valentina Bonetto; Caterina Bendotti; Giovanni Nardo
Journal:  Cell Mol Life Sci       Date:  2021-12-22       Impact factor: 9.261

5.  The Neurotoxicity of Vesicles Secreted by ALS Patient Myotubes Is Specific to Exosome-Like and Not Larger Subtypes.

Authors:  Ekene Anakor; Vanessa Milla; Owen Connolly; Cecile Martinat; Pierre Francois Pradat; Julie Dumonceaux; William Duddy; Stephanie Duguez
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

Review 6.  Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling.

Authors:  Babak Arjmand; Shayesteh Kokabi Hamidpour; Zahra Rabbani; Akram Tayanloo-Beik; Fakher Rahim; Hamid Reza Aghayan; Bagher Larijani
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.